(Article 223-16 of the General Regulations of the Autorité des Marchés Financiers)
Market : NYSE Euronext Paris ISIN Code: FR 0010417345
| Date | Total number of shares | Total number of voting rights |
| 09/30/2024 | 96,501,526 | Total gross of voting rights: 96,501,526 |
| Total net* of voting rights: 96,199,467 |
* Net total = total number of voting rights attached to shares – shares without voting rights
| Last Trade: | US$8.56 |
| Daily Change: | -0.84 -8.94 |
| Daily Volume: | 40,202 |
| Market Cap: | US$175.650M |
January 08, 2025 December 11, 2024 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
